Advanced Enzyme Technologies

Advanced Enzyme delivered a record quarter with revenue of ₹203.4 croreCurrent reported value: ₹203.4 crore. No comparable prior figure is available in the source record. (+22Current reported value: 22. No comparable prior figure is available in the source record.% YoY) and EBITDA of ₹63.2 croreCurrent reported value: ₹63.2 crore. No comparable prior figure is available in the source record. (+39% YoY), driven by strong volume growth in human healthcare (up 24% YoY) and biocatalysis. PAT surged 69% YoYCurrent reported value: 69% YoY. No comparable prior figure is available in the source record. to ₹45.3 croreCurrent reported value: ₹45.3 crore. No comparable prior figure is available in the source record., with margins steady at 31Current reported value: 31. No comparable prior figure is available in the source record.%. The India business grew ~50% YoY, while US remained soft due to tariff uncertainty and inflation. Management expects double-digit growth in FY27, supported by new R&D facility operational in H2, EU approval for an anti-inflammatory product, and capacity expansion plans. Key risk: US tariff and inflation headwinds could pressure margins and delay recovery.